You are here

Palforzia

Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia

Fierce Pharma

Tue, 09/5/23 - 11:32 am

Stallergenes Greer

Nestlé to Sell Off Peanut Allergy Treatment, Not the Blockbuster They Hoped

Motley Fool

Tue, 11/29/22 - 11:00 pm

Aimmune Therapeutics

NICE backs Aimmune’s peanut allergy drug Palforzia for children

Pharmaforum

Mon, 12/27/21 - 11:14 am

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

Endpoints

Tue, 09/15/20 - 11:01 am

Nestle pays $2 billion to secure Aimmune’s allergy treatment

CNBC

Mon, 08/31/20 - 10:54 am

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

Motley Fool

Thu, 04/16/20 - 11:43 pm

DBV Technologies

Aimmune Therapeutics

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Xconomy

Tue, 03/24/20 - 10:20 am

Aimmune Therapeutics

drug manufacturing

Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor

Fierce Biotech

Wed, 02/5/20 - 09:58 am

Aimmune wins approval for peanut immunotherapy, charges 10k+

Endpoints

Sat, 02/1/20 - 11:54 pm

FDA decision nears on Aimmune's contested peanut allergy drug

BioPharma Dive

Fri, 01/24/20 - 12:07 pm

DBV Technologies

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Motley Fool

Fri, 01/10/20 - 10:42 am

Aimmune Therapeutics

Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug

NPR

Mon, 09/23/19 - 07:30 pm

Aimmune Therapeutics

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Biopharma Dive

Fri, 09/13/19 - 07:05 pm

An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

Stat

Fri, 09/13/19 - 10:18 am

advisory panels

Aimmune Therapeutics

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Endpoints

Wed, 09/11/19 - 10:27 am